title: Fasting and post-methionine homocysteine levels in NIDDM. Determinants and correlations with retinopathy, albuminuria, and cardiovascular disease.
abstract: OBJECTIVE
  The increased cardiovascular risk in subjects with NIDDM is partly explained by an association with established risk factors like hypertension, dyslipidemia, and obesity. Mild hyperhomocysteinemia has emerged as a new risk factor for cardiovascular disease. The purpose of this study was to assess its role in NIDDM.
  
  
  METHODS
  We studied predictors of homocysteine levels and correlations between homocysteine and (micro-)albuminuria, retinopathy, and history of cardiovascular disease in normotensive NIDDM subjects under stable metabolic control. This was done in 85 NIDDM subjects by measuring fasting and post-methionine-loading homocysteine levels together with blood pressure, BMI, serum cholesterol, triglyceride, HDL cholesterol, folate, vitamin B12, pyridoxal-5-phosphate, HbA1c, and (micro-)albuminuria and creatinine clearance in triplicate 24-h urine samples. The relationship between micro- and macrovascular complications and fasting homocysteine only was studied in an additional 65 subjects, giving a total of 150 subjects.
  
  
  RESULTS
  In multiple regression analysis, significant (P < 0.05) predictors of fasting homocysteine were low-normal values of creatinine clearance (threshold effect at < 80 ml.min-1 .1.73 m-2), folate (< 20 nmol/l), and vitamin B12 (< 350 pmol/l), and postmenopausal status in women. Determinants of post-methionine homocysteine were pyridoxal-5-phosphate levels < 80 nmol/l, creatinine clearance, and sex (higher levels in women). Hyperhomocysteinemia did not cluster with other cardiovascular risk factors, like hypertension, obesity, or dyslipidemia. Regarding cardiovascular complications, fasting homocysteine, but not post-methionine homocysteine, was higher in subjects with a history of cardiovascular disease. There was a stepwise increase in the prevalence of subjects with cardiovascular disease with increasing fasting homocysteine. The prevalence of cardiovascular disease was 19.4% in the bottom quartile of fasting homocysteine, versus 55.0% in the top quartile (P for trend < 0.01). Neither fasting homocysteine nor post-methionine homocysteine correlated with (micro-)albuminuria or with retinopathy.
  
  
  CONCLUSIONS
  The findings suggest that homocysteine levels in NIDDM rise even with modest deterioration of renal function and when vitamin status is in the low to low-normal range. Fasting homocysteine correlates with macrovascular disease, but we found no evidence of a correlation with retinopathy or (micro-)albuminuria. Post-methionine homocysteine levels do not show a correlation with micro- or macrovascular complications.
authors.affiliation: Department of Internal Medicine, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands.
authors.forename: Y M
authors.initials: YM
authors.lastname: Smulders
authors.forename: M
authors.initials: M
authors.lastname: Rakic
authors.forename: E H
authors.initials: EH
authors.lastname: Slaats
authors.forename: M
authors.initials: M
authors.lastname: Treskes
authors.forename: E J
authors.initials: EJ
authors.lastname: Sijbrands
authors.forename: D A
authors.initials: DA
authors.lastname: Odekerken
authors.forename: C D
authors.initials: CD
authors.lastname: Stehouwer
authors.forename: J
authors.initials: J
authors.lastname: Silberbusch
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000419:Albuminuria / Q000097:blood*; D000704:Analysis of Variance; D001794:Blood Pressure; D002318:Cardiovascular Diseases / Q000097:blood* / Q000150:complications; D003404:Creatinine / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications / Q000503:physiopathology; D003928:Diabetic Nephropathies / Q000097:blood*; D003930:Diabetic Retinopathy / Q000097:blood*; D005215:Fasting; D005260:Female; D005492:Folic Acid / Q000097:blood; D006710:Homocysteine / Q000097:blood*; D006801:Humans; D008297:Male; D008715:Methionine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008875:Middle Aged; D017698:Postmenopause; D017697:Premenopause; D011732:Pyridoxal Phosphate / Q000097:blood; D012044:Regression Analysis; D012307:Risk Factors; D014805:Vitamin B 12 / Q000097:blood
chemical_list: D006710:Homocysteine; D011732:Pyridoxal Phosphate; D005492:Folic Acid; D008715:Methionine; D003404:Creatinine; D014805:Vitamin B 12